Massachusetts Financial Services Co. MA Has $25.41 Million Stock Holdings in Caris Life Sciences, Inc. $CAI

Massachusetts Financial Services Co. MA lessened its stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 3.1% during the 4th quarter, HoldingsChannel reports. The firm owned 941,639 shares of the company’s stock after selling 29,691 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Caris Life Sciences were worth $25,405,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CAI. Olistico Wealth LLC acquired a new position in Caris Life Sciences during the fourth quarter valued at approximately $31,000. Diversified Trust Co. acquired a new stake in shares of Caris Life Sciences in the fourth quarter worth $540,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Caris Life Sciences in the fourth quarter worth $1,584,000. Finally, Zevenbergen Capital Investments LLC acquired a new stake in shares of Caris Life Sciences in the fourth quarter worth $14,655,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CAI. Evercore set a $38.00 price objective on shares of Caris Life Sciences in a research note on Monday, January 5th. Canaccord Genuity Group lowered their price objective on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. Wall Street Zen upgraded shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. The Goldman Sachs Group began coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Piper Sandler began coverage on shares of Caris Life Sciences in a research note on Friday, April 10th. They issued a “neutral” rating and a $21.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Caris Life Sciences has a consensus rating of “Hold” and a consensus price target of $28.86.

Caris Life Sciences Price Performance

Shares of CAI stock opened at $20.95 on Thursday. The company has a market capitalization of $5.92 billion and a PE ratio of -116.39. Caris Life Sciences, Inc. has a one year low of $16.28 and a one year high of $42.50. The business has a fifty day moving average price of $19.39. The company has a debt-to-equity ratio of 0.66, a quick ratio of 7.35 and a current ratio of 7.85.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. The firm’s revenue for the quarter was up 125.4% compared to the same quarter last year. During the same period last year, the business earned ($1.73) earnings per share.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.